查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1955483

2026年全球吸入式生技藥品市場報告

Inhalable Biologics Global Market Report 2026
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年來，吸入式生物製藥市場規模迅速擴張，預計將從2025年的32.2億美元成長到2026年的37.3億美元，複合年成長率達15.7%。過去幾年的成長可歸因於呼吸系統疾病盛行率的上升、注射式生物製藥的局限性、吸入裝置技術的進步、生物製藥研發管線的擴展以及醫院呼吸系統護理需求的增加。

預計未來幾年吸入生物製藥市場將快速成長，到2030年市場規模將達到66.7億美元，複合年成長率（CAGR）為15.6%。預測期內的成長可能受多種因素驅動，包括慢性呼吸系統疾病的增加、吸入生物製藥範圍從呼吸系統擴展到其他領域、患者對非侵入性治療方法的偏好日益成長、製劑穩定性的提高以及對肺部給藥研究投入的增加。預測期內的關鍵趨勢包括：全身生物製藥肺部給藥方式的擴展、生物製藥乾粉吸入器的使用日益增多、對靶向肺部給藥的日益關注、吸入式單株抗體的研發不斷推進以及患者更易接受的非侵入性生物療法的普及。

預計未來幾年，呼吸系統疾病盛行率的上升將推動吸入生物製藥市場的成長。呼吸系統疾病是指影響肺部及呼吸系統其他組成部分（包括氣道和鼻腔）的疾病和失調。這些疾病的增加主要是由於空氣污染加劇，有害顆粒物和污染物的暴露會加重氣喘、慢性阻塞性肺病（COPD）和肺癌等疾病。吸入生物製藥的優點在於能夠將標靶治療直接輸送到肺部，有助於減輕發炎、改善肺功能，同時最大限度地減少全身副作用，是治療呼吸系統疾病的理想選擇。例如，根據澳洲政府機構澳洲健康與福利研究所 (AIHW) 2024 年 6 月發布的報告，預計到 2023 年，慢性阻塞性肺病 (COPD) 將佔總疾病負擔的 3.6%，佔呼吸系統疾病負擔的 50%。因此，呼吸系統疾病盛行率的上升是推動吸入生物製藥市場擴張的關鍵因素。

吸入式生物製藥市場的主要企業正致力於開發創新解決方案，例如吸入式胰島素，以提高患者依從性並實現快速血糖控制。吸入式胰島素是一種透過肺部吸入而非注射或胰島素幫浦給藥的胰島素製劑。這種方法是將粉狀或霧化的胰島素吸入肺部，胰島素經由肺部吸收後迅速進入血液，進而調節血糖值。例如，2025年2月，印度製藥公司Cipla Limited的Afrezza獲得了印度中央藥品標準控制組織（CDSCO）的監管核准。 Afrezza是目前全球起效最快的吸入式胰島素，為第1型和第2型糖尿病成人患者提供了一種突破性的無針治療選擇。這款超速效胰島素在吸入後12至15分鐘內即可發揮作用，並能高度模擬人體對餐後的自然胰島素反應，有助於改善血糖控制。此外，吸入式胰島素為每日多次注射提供了更方便的替代方案，特別適合那些有注射焦慮症的人，並有助於提高胰島素治療的依從性。

目錄

第1章執行摘要

第2章 市場特徵

  • 市場定義和範圍
  • 市場區隔
  • 主要產品和服務概述
  • 全球吸入式生技藥品市場：吸引力評分及分析
  • 成長潛力分析、競爭評估、策略契合度評估、風險狀況評估

第3章 市場供應鏈分析

  • 供應鏈與生態系概述
  • 主要原料、資源和供應商清單
  • 主要經銷商和通路合作夥伴名單
  • 主要最終用戶列表

第4章 全球市場趨勢與策略

  • 關鍵技術和未來趨勢
    • 生物技術、基因組學和精準醫學
    • 數位化、雲端運算、巨量資料、網路安全
    • 工業4.0和智慧製造
    • 人工智慧（AI）和自主人工智慧
    • 永續性、氣候技術和循環經濟
  • 主要趨勢
    • 擴大全身性生物製藥製劑的肺部給藥途徑
    • 擴大生物製藥乾粉吸入器的應用
    • 人們越來越關注標靶肺部給藥
    • 吸入式單株抗體的研發日益增多
    • 推出對病人友善、非侵入性的生物療法

第5章 終端用戶產業市場分析

  • 醫院
  • 呼吸系統醫療設備專科診所
  • 製藥和生物技術公司
  • 研究和學術機構
  • 居家醫療保健服務提供者

第6章 市場：宏觀經濟情景，包括利率、通貨膨脹、地緣政治、貿易戰和關稅的影響、關稅戰和貿易保護主義對供應鏈的影響，以及新冠疫情對市場的影響

第7章 全球策略分析架構、目前市場規模、市場對比及成長率分析

  • 全球吸入式生技藥品市場：PESTEL 分析（政治、社會、技術、環境、法律因素、促進因素與限制因素）
  • 全球吸入性生技藥品市場規模、對比及成長率分析
  • 全球吸入式生技藥品市場表現：規模與成長，2020-2025年
  • 全球吸入式生技藥品市場預測：規模與成長，2025-2030年，2035年預測

第8章 全球潛在市場規模（TAM）

第9章 市場細分

  • 按類型
  • 胜肽和蛋白質、疫苗、單株抗體、基於RNAi的療法以及其他類型
  • 按劑型
  • 乾粉吸入器、定量吸入器、霧化器和其他劑型
  • 透過分銷管道
  • 醫院藥局、零售藥局、網路藥局
  • 透過使用
  • 呼吸系統疾病、糖尿病、癌症及其他適應症
  • 按類型細分：胜肽和蛋白質
  • 胰島素、生長激素、酵素替代療法以及其他胜肽和蛋白質
  • 按類型細分：疫苗
  • 流感疫苗和其他呼吸道疫苗
  • 按類型細分：單株抗體
  • 呼吸道單株抗體、免疫調節單株抗體和其他單株抗體
  • 按類型細分：基於RNAi的療法
  • 用於治療呼吸系統疾病的 RNA 藥物和其他基於 RNAi 的療法
  • 按類型細分：其他類型
  • 基因療法、吸入式小分子藥物和其他創新吸入式生物製藥

第10章 區域與國家分析

  • 全球吸入式生技藥品市場：區域分析、預測與趨勢（2020-2025年、2025-2030年預測、2035年預測）
  • 全球吸入式生技藥品市場：國家、市場表現及預測，2020-2025年、2025-2030年預測、2035年預測

第11章 亞太市場

第12章：中國市場

第13章 印度市場

第14章 日本市場

第15章：澳洲市場

第16章 印尼市場

第17章 韓國市場

第18章 台灣市場

第19章 東南亞市場

第20章：西歐市場

第21章英國市場

第22章 德國市場

第23章：法國市場

第24章：義大利市場

第25章：西班牙市場

第26章 東歐市場

第27章：俄羅斯市場

第28章 北美市場

第29章：美國市場

第30章：加拿大市場

第31章 南美洲市場

第32章：巴西市場

第33章 中東市場

第34章：非洲市場

第35章 市場監理與投資環境

第36章：競爭格局與公司概況

  • 吸入式生技藥品市場：競爭格局及市場佔有率（2024年）
  • 吸入式生技藥品市場：公司估值矩陣
  • 吸入式生技藥品市場：公司概況
    • Bayer AG
    • Sanofi SA
    • AstraZeneca plc
    • Novartis AG
    • GlaxoSmithKline plc

第37章：其他領先和創新企業

  • Moderna Inc., Pfizer Inc., BioNTech SE, Teva Pharmaceuticals, Baxter International, Lonza Group AG, CanSino Biologics Inc., Cipla Ltd., Insmed Incorporated, Kamada Pharmaceuticals, Vectura Group plc, F. Hoffmann-La Roche Ltd, Iconovo AB, Synairgen plc, Ab Initio Pharma LLC

第38章 全球市場競爭基準分析與儀錶板

第39章 重大併購

第40章：高潛力市場國家、細分市場與策略

  • 2030年吸入式生技藥品市場：提供新機會的國家
  • 2030年吸入式生技藥品市場：蘊藏新機會的細分市場
  • 2030年吸入式生技藥品市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第41章附錄

簡介目錄
Product Code: PH5MIBIO03_G26Q1

Inhalable biologics are biologic drugs delivered through the respiratory tract via inhalation. This route of administration enables targeted treatment of lung conditions or systemic therapy by directly reaching the lungs, improving drug efficacy, and minimizing side effects.

The primary types of inhalable biologics include peptides and proteins, vaccines, monoclonal antibodies, RNAi-based therapeutics, and others. Peptide and protein therapeutics are bioactive compounds developed to regulate specific cellular pathways or to replace missing or deficient proteins. These therapeutics are available in multiple dosage forms, such as dry powder inhalers, metered dose inhalers, nebulizers, and others, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. They are used in the treatment of respiratory diseases, diabetes, cancer, and other conditions.

Tariffs have impacted the inhalable biologics market by increasing costs for imported biologic raw materials, inhalation devices, and precision manufacturing equipment, affecting overall production economics. These impacts are most evident in dry powder inhalers and nebulizer-based biologic formulations, particularly across Asia-Pacific and Europe where device manufacturing and biologic sourcing are concentrated. Higher tariffs have contributed to pricing pressure in hospital and retail pharmacy channels. However, tariffs have also encouraged regional manufacturing, localized device sourcing, and innovation in cost-efficient inhalable biologic production.

The inhalable biologics market research report is one of a series of new reports from The Business Research Company that provides inhalable biologics market statistics, including inhalable biologics industry global market size, regional shares, competitors with a inhalable biologics market share, detailed inhalable biologics market segments, market trends and opportunities, and any further data you may need to thrive in the inhalable biologics industry. This inhalable biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The inhalable biologics market size has grown rapidly in recent years. It will grow from $3.22 billion in 2025 to $3.73 billion in 2026 at a compound annual growth rate (CAGR) of 15.7%. The growth in the historic period can be attributed to rising prevalence of respiratory diseases, limitations of injectable biologics, advances in inhalation device technology, growing biologics pipeline, increasing hospital-based respiratory care.

The inhalable biologics market size is expected to see rapid growth in the next few years. It will grow to $6.67 billion in 2030 at a compound annual growth rate (CAGR) of 15.6%. The growth in the forecast period can be attributed to growth in chronic respiratory disorders, expansion of inhalable biologics beyond respiratory indications, increasing patient preference for non-invasive therapies, advancements in formulation stability, rising investments in pulmonary drug delivery research. Major trends in the forecast period include expansion of pulmonary delivery for systemic biologics, growing use of dry powder inhalers for biologics, rising focus on targeted lung drug delivery, increasing development of inhalable monoclonal antibodies, adoption of patient-friendly non-invasive biologic therapies.

The rising prevalence of respiratory conditions is expected to drive the growth of the inhalable biologics market in the coming years. Respiratory conditions encompass diseases and disorders that affect the lungs and other components of the respiratory system, including the airways and nasal passages. The growing occurrence of these conditions is largely attributed to increasing air pollution, which worsens illnesses such as asthma, chronic obstructive pulmonary disease (COPD), and lung cancer by exposing individuals to harmful particulate matter and pollutants. Inhalable biologics offer advantages for treating respiratory conditions by delivering targeted therapies directly to the lungs, helping to reduce inflammation and enhance lung function while minimizing systemic side effects. For example, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, COPD accounted for 3.6% of the total disease burden and 50% of the respiratory disease burden in 2023. Consequently, the increasing incidence of respiratory conditions is a significant factor driving the expansion of the inhalable biologics market.

Major companies operating in the inhalable biologics market are emphasizing the development of innovative solutions, such as inhaled insulin, to enhance patient adherence and enable rapid glycemic control. Inhaled insulin is an insulin formulation administered through the lungs via inhalation rather than by injections or insulin pumps. This approach involves inhaling a powdered or aerosolized form of insulin, which is absorbed through the pulmonary system and rapidly enters the bloodstream to regulate blood glucose levels. For example, in February 2025, Cipla Limited, an India-based pharmaceutical company, obtained regulatory approval from the Central Drugs Standard Control Organization for Afrezza, the world's fastest inhaled insulin, providing a groundbreaking, needle-free treatment option for adults with type 1 and type 2 diabetes. This ultra-rapid-acting insulin begins working within 12 to 15 minutes after inhalation, closely replicating the body's natural insulin response to meals and supporting improved blood sugar management. Inhaled insulin also offers a more convenient alternative to multiple daily injections, particularly benefiting individuals with injection-related anxiety and improving adherence to insulin therapy.

In October 2025, Merck & Co., Inc., a US-based provider of pharmaceuticals, vaccines, and cardiopulmonary therapies, acquired Verona Pharma for $10 billion. Through this acquisition, Merck sought to strengthen and diversify its cardiopulmonary and respiratory portfolio by adding a novel inhaled therapy. Verona Pharma is a UK-based biopharmaceutical company focused on respiratory diseases, with its primary product being Ohtuvayre (ensifentrine), a first-in-class inhaled dual PDE3/4 inhibitor for the treatment of COPD.

Major companies operating in the inhalable biologics market are Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Moderna Inc., Pfizer Inc. and BioNTech SE, Teva Pharmaceuticals, Baxter International, Lonza Group AG, CanSino Biologics Inc., Cipla Ltd., Insmed Incorporated, Kamada Pharmaceuticals, Vectura Group plc, F. Hoffmann-La Roche Ltd, Iconovo AB, Synairgen plc, Ab Initio Pharma LLC, Nanopharm Ltd, Ocugen Inc., MannKind Corporation

North America was the largest region in the inhalable biologics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inhalable biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the inhalable biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The inhalable biologics market consists of sales of inhaled antibodies, inhalable mRNA-based therapeutics, inhaled vaccines, inhaled enzyme replacement therapies, and inhalable gene therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Inhalable Biologics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses inhalable biologics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for inhalable biologics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The inhalable biologics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Type: Peptides And Proteins; Vaccines; Monoclonal Antibodies; RNAi-Based Therapeutics; Other Types
  • 2) By Dosage Form: Dry Powder Inhalers; Metered Dose Inhalers; Nebulizers; Other Dosage Forms
  • 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • 4) By Application: Respiratory Diseases; Diabetes; Cancer; Other Applications
  • Subsegments:
  • 1) By Peptides And Proteins: Insulin; Growth Hormones; Enzyme Replacement Therapies; Other Peptides And Proteins
  • 2) By Vaccines: Influenza Vaccines; Other Respiratory Vaccines
  • 3) By Monoclonal Antibodies: Respiratory Monoclonal Antibodies; Immunomodulatory Monoclonal Antibodies; Other Monoclonal Antibodies
  • 4) By RNAi-Based Therapeutics: RNA-Based Drugs For Respiratory Diseases; Other RNAi-Based Therapeutics
  • 5) By Other Types: Gene Therapies; Small Molecule Inhalable Drugs; Other Innovative Inhalable Biologics
  • Companies Mentioned: Bayer AG; Sanofi SA; AstraZeneca plc; Novartis AG; GlaxoSmithKline plc; Moderna Inc.; Pfizer Inc. and BioNTech SE; Teva Pharmaceuticals; Baxter International; Lonza Group AG; CanSino Biologics Inc.; Cipla Ltd.; Insmed Incorporated; Kamada Pharmaceuticals; Vectura Group plc; F. Hoffmann-La Roche Ltd; Iconovo AB; Synairgen plc; Ab Initio Pharma LLC; Nanopharm Ltd; Ocugen Inc.; MannKind Corporation
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Inhalable Biologics Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Inhalable Biologics Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Inhalable Biologics Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Inhalable Biologics Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.3 Industry 4.0 & Intelligent Manufacturing
    • 4.1.4 Artificial Intelligence & Autonomous Intelligence
    • 4.1.5 Sustainability, Climate Tech & Circular Economy
  • 4.2. Major Trends
    • 4.2.1 Expansion Of Pulmonary Delivery For Systemic Biologics
    • 4.2.2 Growing Use Of Dry Powder Inhalers For Biologics
    • 4.2.3 Rising Focus On Targeted Lung Drug Delivery
    • 4.2.4 Increasing Development Of Inhalable Monoclonal Antibodies
    • 4.2.5 Adoption Of Patient-Friendly Non-Invasive Biologic Therapies

5. Inhalable Biologics Market Analysis Of End Use Industries

  • 5.1 Hospitals
  • 5.2 Specialty Pulmonology Clinics
  • 5.3 Pharmaceutical And Biotechnology Companies
  • 5.4 Research And Academic Institutes
  • 5.5 Homecare Providers

6. Inhalable Biologics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Inhalable Biologics Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Inhalable Biologics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Inhalable Biologics Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Inhalable Biologics Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Inhalable Biologics Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Inhalable Biologics Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Inhalable Biologics Market Segmentation

  • 9.1. Global Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Peptides And Proteins, Vaccines, Monoclonal Antibodies, RNAi-Based Therapeutics, Other Types
  • 9.2. Global Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Dry Powder Inhalers, Metered Dose Inhalers, Nebulizers, Other Dosage Forms
  • 9.3. Global Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
  • 9.4. Global Inhalable Biologics Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Respiratory Diseases, Diabetes, Cancer, Other Applications
  • 9.5. Global Inhalable Biologics Market, Sub-Segmentation Of Peptides And Proteins, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Insulin, Growth Hormones, Enzyme Replacement Therapies, Other Peptides And Proteins
  • 9.6. Global Inhalable Biologics Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Influenza Vaccines, Other Respiratory Vaccines
  • 9.7. Global Inhalable Biologics Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Respiratory Monoclonal Antibodies, Immunomodulatory Monoclonal Antibodies, Other Monoclonal Antibodies
  • 9.8. Global Inhalable Biologics Market, Sub-Segmentation Of RNAi-Based Therapeutics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • RNA-Based Drugs For Respiratory Diseases, Other RNAi-Based Therapeutics
  • 9.9. Global Inhalable Biologics Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Gene Therapies, Small Molecule Inhalable Drugs, Other Innovative Inhalable Biologics

10. Inhalable Biologics Market Regional And Country Analysis

  • 10.1. Global Inhalable Biologics Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Inhalable Biologics Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Inhalable Biologics Market

  • 11.1. Asia-Pacific Inhalable Biologics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Inhalable Biologics Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Inhalable Biologics Market

  • 12.1. China Inhalable Biologics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Inhalable Biologics Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Inhalable Biologics Market

  • 13.1. India Inhalable Biologics Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Inhalable Biologics Market

  • 14.1. Japan Inhalable Biologics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Inhalable Biologics Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Inhalable Biologics Market

  • 15.1. Australia Inhalable Biologics Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Inhalable Biologics Market

  • 16.1. Indonesia Inhalable Biologics Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Inhalable Biologics Market

  • 17.1. South Korea Inhalable Biologics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Inhalable Biologics Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Inhalable Biologics Market

  • 18.1. Taiwan Inhalable Biologics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Inhalable Biologics Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Inhalable Biologics Market

  • 19.1. South East Asia Inhalable Biologics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Inhalable Biologics Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Inhalable Biologics Market

  • 20.1. Western Europe Inhalable Biologics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Inhalable Biologics Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Inhalable Biologics Market

  • 21.1. UK Inhalable Biologics Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Inhalable Biologics Market

  • 22.1. Germany Inhalable Biologics Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Inhalable Biologics Market

  • 23.1. France Inhalable Biologics Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Inhalable Biologics Market

  • 24.1. Italy Inhalable Biologics Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Inhalable Biologics Market

  • 25.1. Spain Inhalable Biologics Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Inhalable Biologics Market

  • 26.1. Eastern Europe Inhalable Biologics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Inhalable Biologics Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Inhalable Biologics Market

  • 27.1. Russia Inhalable Biologics Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Inhalable Biologics Market

  • 28.1. North America Inhalable Biologics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Inhalable Biologics Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Inhalable Biologics Market

  • 29.1. USA Inhalable Biologics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Inhalable Biologics Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Inhalable Biologics Market

  • 30.1. Canada Inhalable Biologics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Inhalable Biologics Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Inhalable Biologics Market

  • 31.1. South America Inhalable Biologics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Inhalable Biologics Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Inhalable Biologics Market

  • 32.1. Brazil Inhalable Biologics Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Inhalable Biologics Market

  • 33.1. Middle East Inhalable Biologics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Inhalable Biologics Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Inhalable Biologics Market

  • 34.1. Africa Inhalable Biologics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Inhalable Biologics Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Inhalable Biologics Market Regulatory and Investment Landscape

36. Inhalable Biologics Market Competitive Landscape And Company Profiles

  • 36.1. Inhalable Biologics Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Inhalable Biologics Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Inhalable Biologics Market Company Profiles
    • 36.3.1. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

37. Inhalable Biologics Market Other Major And Innovative Companies

  • Moderna Inc., Pfizer Inc., BioNTech SE, Teva Pharmaceuticals, Baxter International, Lonza Group AG, CanSino Biologics Inc., Cipla Ltd., Insmed Incorporated, Kamada Pharmaceuticals, Vectura Group plc, F. Hoffmann-La Roche Ltd, Iconovo AB, Synairgen plc, Ab Initio Pharma LLC

38. Global Inhalable Biologics Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Inhalable Biologics Market

40. Inhalable Biologics Market High Potential Countries, Segments and Strategies

  • 40.1 Inhalable Biologics Market In 2030 - Countries Offering Most New Opportunities
  • 40.2 Inhalable Biologics Market In 2030 - Segments Offering Most New Opportunities
  • 40.3 Inhalable Biologics Market In 2030 - Growth Strategies
    • 40.3.1 Market Trend Based Strategies
    • 40.3.2 Competitor Strategies

41. Appendix

  • 41.1. Abbreviations
  • 41.2. Currencies
  • 41.3. Historic And Forecast Inflation Rates
  • 41.4. Research Inquiries
  • 41.5. The Business Research Company
  • 41.6. Copyright And Disclaimer